Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Manic Episode Clear all

Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171

View directory record Official record

Conditions: Bipolar Disorder, Schizoaffective Disorder
Interventions: Probiotic Supplement, Inert Compound; Dietary Supplement
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 65 Years

Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Jan 6, 2019 · Synced May 22, 2026, 1:26 AM EDT

Completed Not applicable Interventional

A Study of Spoken Language in Mania

NCT05956340

View directory record Official record

Conditions: Manic Episode, Bipolar I Disorder
Interventions: Research interview; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 22, 2026, 1:26 AM EDT

Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726

View directory record Official record

Conditions: Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more

Source: ClinicalTrials.gov public record

Updated Jun 15, 2021 · Synced May 22, 2026, 1:26 AM EDT

Recruiting Phase 2 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

NCT07046494

View directory record Official record

Conditions: Bipolar 1 Disorder
Interventions: RAP-219, Placebo; Drug · Other
Lead sponsor: Rapport Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Chino, California + 18 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 1:26 AM EDT

Recruiting Phase 3 Interventional

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

NCT06462586

View directory record Official record

Conditions: Bipolar Disorder, Manic
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 23
States / cities: Rogers, Arkansas • Bellflower, California • Culver City, California + 18 more

Source: ClinicalTrials.gov public record

Updated Jun 30, 2025 · Synced May 22, 2026, 1:26 AM EDT

Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

NCT06608641

View directory record Official record

Conditions: Bipolar 1 Disorder
Interventions: Endoxifen enteric-coated tablet (8 mg), Placebo Tablets; Drug
Lead sponsor: Jina Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Cerritos, California • Los Angeles, California • Orange, California + 8 more

Source: ClinicalTrials.gov public record

Updated Mar 16, 2025 · Synced May 22, 2026, 1:26 AM EDT

Terminated Phase 2 Interventional

BHV-7000 Open-Label Extension Bipolar Mania Study

NCT06423794

View directory record Official record

Conditions: Bipolar Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 32
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more

Source: ClinicalTrials.gov public record

Updated Dec 15, 2025 · Synced May 22, 2026, 1:26 AM EDT

Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020

View directory record Official record

Conditions: Bipolar Disorder
Interventions: divalproex ER, quetiapine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: San Diego, California

Source: ClinicalTrials.gov public record

Updated Sep 10, 2019 · Synced May 22, 2026, 1:26 AM EDT

Terminated Phase 3 Interventional Results available

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927

View directory record Official record

Conditions: Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years

Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 23
States / cities: Dothan, Alabama • Downey, California • Miami, Florida + 19 more

Source: ClinicalTrials.gov public record

Updated Feb 7, 2016 · Synced May 22, 2026, 1:26 AM EDT

Completed Phase 3 Interventional

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

NCT01396291

View directory record Official record

Conditions: Bipolar 1 Disorder
Interventions: asenapine, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older

Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 30
States / cities: Anaheim, California • Chino, California • Escondido, California + 25 more

Source: ClinicalTrials.gov public record

Updated Dec 3, 2015 · Synced May 22, 2026, 1:26 AM EDT

Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443

View directory record Official record

Conditions: Bipolar Disorder
Interventions: Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 29
States / cities: Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more

Source: ClinicalTrials.gov public record

Updated Apr 17, 2023 · Synced May 22, 2026, 1:26 AM EDT

Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229

View directory record Official record

Conditions: Bipolar Disorder
Interventions: Licarbazepine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 16
States / cities: Little Rock, Arkansas • Cerritos, California • San Diego, California + 12 more

Source: ClinicalTrials.gov public record

Updated Feb 22, 2017 · Synced May 22, 2026, 1:26 AM EDT

Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

NCT00374920

View directory record Official record

Conditions: Bipolar Disorder With Manic or Mixed Episodes
Interventions: MEM 1003; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 21
States / cities: Little Rock, Arkansas • Garden Grove, California • Riverside, California + 15 more

Source: ClinicalTrials.gov public record

Updated May 5, 2008 · Synced May 22, 2026, 1:26 AM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971

View directory record Official record

Conditions: Bipolar Disorder
Interventions: Olanzapine, Paliperidone ER, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more

Source: ClinicalTrials.gov public record

Updated Apr 14, 2015 · Synced May 22, 2026, 1:26 AM EDT